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http://www.microbialcellfactories.com/content/12/1/37RESEARCH Open AccessHigh throughput screening identifies disulfide
isomerase DsbC as a very efficient partner for
recombinant expression of small disulfide-rich
proteins in E. coli
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Badreddine Douzi2, Natalie J Saez2, Mireille Moutiez1, Denis Servent1, Muriel Gondry1, Robert Thaï1,
Philippe Cuniasse1, Renaud Vincentelli2† and Vincent Dive1†Abstract
Background: Disulfide-rich proteins or DRPs are versatile bioactive compounds that encompass a wide variety of
pharmacological, therapeutic, and/or biotechnological applications. Still, the production of DRPs in sufficient
quantities is a major bottleneck for their complete structural or functional characterization. Recombinant expression
of such small proteins containing multiple disulfide bonds in the bacteria E. coli is considered difficult and general
methods and protocols, particularly on a high throughput scale, are limited.
Results: Here we report a high throughput screening approach that allowed the systematic investigation of the
solubilizing and folding influence of twelve cytoplasmic partners on 28 DRPs in the strains BL21 (DE3) pLysS,
Origami B (DE3) pLysS and SHuffle® T7 Express lysY (1008 conditions). The screening identified the conditions
leading to the successful soluble expression of the 28 DRPs selected for the study. Amongst 336 conditions tested
per bacterial strain, soluble expression was detected in 196 conditions using the strain BL21 (DE3) pLysS, whereas
only 44 and 50 conditions for soluble expression were identified for the strains Origami B (DE3) pLysS and SHuffle®
T7 Express lysY respectively. To assess the redox states of the DRPs, the solubility screen was coupled with mass
spectrometry (MS) to determine the exact masses of the produced DRPs or fusion proteins. To validate the results
obtained at analytical scale, several examples of proteins expressed and purified to a larger scale are presented
along with their MS and functional characterization.
Conclusions: Our results show that the production of soluble and functional DRPs with cytoplasmic partners is
possible in E. coli. In spite of its reducing cytoplasm, BL21 (DE3) pLysS is more efficient than the Origami B (DE3)
pLysS and SHuffle® T7 Express lysY trxB-/gor- strains for the production of DRPs in fusion with solubilizing partners.
However, our data suggest that oxidation of the proteins occurs ex vivo. Our protocols allow the production of a
large diversity of DRPs using DsbC as a fusion partner, leading to pure active DRPs at milligram scale in many cases.
These results open up new possibilities for the study and development of DRPs with therapeutic or
biotechnological interest whose production was previously a limitation.
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Small proteins containing disulfide bonds are versatile bio-
active compounds that possess important pharmaco-
logical, therapeutic, and/or biotechnological values. There
is a growing interest in the use of small disulfide-rich pro-
teins (DRPs) as therapeutics, as they have several advan-
tages over traditional small molecule drugs due to their
high affinity and selectivity [1]. Small reticulated proteins
have many applications, such as ion channel blockers for
severe chronic pain treatment [2], as scaffolds for the
transfer of hotspot active sites of bigger or more complex
proteins [3,4], as antimicrobial and host-defense peptides
[5] or molecular imaging agents [6]. In most cases, DRPs
are composed of 20 to 120 residues and include between
one to five disulfide bonds that are often crucial for activ-
ity and stability of these proteins. Oxidation of cysteine
residues and proper disulfide pairing are indeed necessary
for the correct spatial distribution of the key functional
residues. Unfortunately, study and development of DRPs
of therapeutic or biotechnological interest are still ham-
pered by the difficulty to produce native and active pro-
teins in sufficient amounts.
E. coli has many well-known advantages as a host for
heterologous protein expression [7]. Various and com-
plementary approaches have been described to produce
native and soluble proteins in this bacterial host. In the
past decade, several high throughput platforms have
been used to identify optimal conditions for the soluble
expression of proteins, notably by varying parameters
such as fusion partners, strains or temperature [8-12].
Surprisingly, whereas several examples of successful
expression of reticulated proteins in E. coli have been
described [13-16], there is, to our knowledge, no study
reporting parallel expression screening of many proteins
containing various numbers of disulfide bonds.
Even if the production of various disulfide-bonded
proteins in E. coli has previously been reported, expres-
sion of proteins with multiple disulfide bonds is still
considered difficult [17]. As shown in vitro for the well-
studied Bovine Pancreatic Trypsin Inhibitor (BPTI), the
folding of disulfide-bonded proteins is often acquired
through the accumulation of disulfide intermediates
[18,19]. For some disulfide-rich proteins, oxidative folding
generates heterogeneous populations of intermediates
containing native but also non-native disulfide-bonded
species, which require isomerization to reach the natively-
folded oxidized state [20,21]. Thus, proteins with disulfide
bonds are especially prone to aggregation due to possible
mispairing of cysteine residues or undesirable intermo-
lecular disulfide bonds. When overexpressed in bacteria
with strong promoters, recombinant proteins often tend
to misfold and accumulate as insoluble aggregates or
inclusion bodies [22]. In many cases, the difficulty in
reaching native conformation increases with thenumber of cysteine residues due to the number of possible
isoforms, but also with the complexity of disulfide bond
patterns. Failure to reach a native and stable conformation
results, in most cases, in either protein aggregation or pro-
teolytic degradation [23].
In past years, many approaches have been developed
to promote the formation of disulfide bonds and the
native folding of disulfide-rich proteins [17]. Exporting
the proteins to the E. coli oxidizing periplasm is an in-
tuitive strategy [24,25], as folding of proteins can be
assisted by the disulfide bond formation system [26-28].
However, secretion of proteins to the periplasm often
leads to low protein levels [28], probably because of the
limited periplasmic volume combined with an insufficient
capacity of the translocation machinery [29]. Because of
these limitations, many strategies consider expression in
the E. coli cytoplasm, even for proteins containing disul-
fide bonds. Oxidation of cysteine thiols in the reducing
cytoplasm of wild-type E. coli is described as unfavorable
for both thermodynamic and kinetic reasons [17,23]. To
overcome this issue, engineered strains like Origami
(DE3) pLysS with an oxidative cytoplasm were developed
[30,31]. These strains contain deletions of both glutathi-
one and thioredoxin reductase genes (gor-, trxB-) along
with an additional mutation in the peroxiredoxin gene
ahpC necessary to restore growth. Some studies indicate
that these strains enhance the accumulation of oxidized
proteins in the cytoplasm [17,32,33]. Several other
engineered strains with altered reducing pathways are de-
scribed to improve production levels of disulfide-bonded
proteins [34,35]. The amount of oxidized protein can be
further enhanced by co-expression of redox-active
enzymes like thioredoxin (Trx), Trx mutants or DsbC in
the cytoplasm of trxB-/gor-strains [30,36]. Thioredoxin
mutants are of particular interest because the two residues
included in the dicysteine active site (CxxC) are effecting
their oxidoreductase activities. Indeed, mutating these two
amino acids shifts the activity from a reductase to an
oxidase in oxidative environments. These characteristics
are described as very useful for the production of proteins
with disulfide bonds [30,37].
In addition to those approaches for promoting the forma-
tion of disulfide bonds, the question of the solubilization of
the protein of interest and its folding intermediates has to
be addressed. Many fusion tags are described to enhance
protein solubility in vivo [38-40]. Several proteins have
been extensively used as fusion partners like glutathi-
one S-transferase (GST) [41], maltose binding protein
(MBP) [42], double Z-domain from staphylococcal protein
A (ZZ) [43] or Gb1-domain from protein G (Gb1) [44].
Some other fusion partners not only have an important
solubilizing effect but also redox properties, which could
be beneficial for disulfide bond formation. From this per-
spective, thioredoxin is not only an oxidoreductase but
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able [45]. For the above purpose, the proteins DsbA
and DsbC, although not as yet explored, could also be of
interest as solubilizing partners for cytoplasmic expres-
sion, if expressed without their signal peptides. Indeed, di-
sulfide isomerase DsbC retains a foldase and chaperonin
activity when used in co-expression in the cytoplasm
[36,46]. Nevertheless, even if several publications report
the positive effect of fusion partners or use of specific
strains on the recombinant expression of specific DRPs,
no general study has yet explored the efficacy of these sys-
tems on a large diversity of DRPs in order to document
general rules for this protein family.
Here we report the results of a high throughput screen
for the soluble expression of small proteins with disul-
fide bonds in the E. coli cytoplasm. Given a set of DRPs;
28 different proteins of variable size (from 25 to 122 aa)
with two to five disulfide bridges, the objective of this
study was to identify the best fusion partners and strains
to provide access to milligram amounts of oxidized and
functional recombinant DRPs.
Results
Study set up
We have selected 28 targets (Additional file 1: Table S1
Data), representing six different folds (ICK, 3FT, Kunitz,
Kazal type, α/β, 310 helix). This set includes proteins for
which functional tests are available to allow the assess-
ment of the correct folding of the targets based on the
preservation of their native binding properties. All these
proteins have an even number of cysteine residues that
are all involved in a disulfide bond. Twelve different
fusion partners targeting the protein into the cytoplasmFusion Par6xHisT7
(B) : GST, MBP, ZZ, GB1 (fusions with
6xHisT7 TEV DRP
(A) : 6HIS (no solubilizing partner) 
Fusion PartnerT7
(C) : Thioredoxins, DsbA, DsbC (fusio
Figure 1 Design of the expression plasmids. All plasmids carry a T7 pro
Etch Virus (TEV) cleavage site and a gene encoding a disulfide-rich protein
fusions without redox properties (B). The 6HIS tag is placed between the fu
(C). Non-redox fusion partners are represented in white boxes while redox
properties of the fusions appears throughout the figures.were selected in our study (Additional file 2: Table S2
Data). In every case a hexa-histidine (6HIS) tag was
introduced to enable the downstream purification of the
fusion proteins using immobilized-nickel affinity chro-
matography. A TEV (Tobacco Etch Virus) protease
cleavage site (ENLYFQ/G) was introduced to enable
removal of the fusion partner. In addition to the 6HIS
affinity tag alone which serves as a reference, the 11
other fusion partners selected in our study include gluta-
thione S-transferase (GST) [41], maltose binding protein
(MBP) [42], double Z-domain from staphylococcal pro-
tein A (ZZ) [43], Gb1-domain from protein G (Gb1)
[44], thioredoxin (Trx) and four of its active site mutants
[30], the disulfide oxidoreductase DsbA and the disulfide
isomerase DsbC from E. coli [47] without their signal
peptides to allow cytoplasmic expression. The four
mutants of Thioredoxin are Trx-A with a DsbA-like
active site (CPHC), Trx-C with a DsbC-like active site
(CGYC), Trx-G with a glutaredoxin-like active site
(CPYC) and Trx-P with a PDI-like active site (CGHC).
All expression vectors were constructed using Gateway
cloning technology (Invitrogen) [48]. A schematic repre-
sentation of each vector can be found in Figure 1. To
benchmark the effect of the strains on the yield of DRPs,
three different E. coli expression strains were used in this
study. BL21 (DE3) pLysS with a reducing cytoplasm, the
Origami B (DE3) pLysS with a more oxidizing cytoplasm
and finally the SHuffle® T7 Express lysY which are simi-
lar to the Origami B (DE3) pLysS (oxidizing cytoplasm)
but was engineered to express also cytoplasmic DsbC
[36]. The screening scheme (Figure 2) is a slightly modi-
fied version of the high throughput protocols described
in detail elsewhere ([9,49]). The culture and expressiontner TEV DRP
out redox properties) 
6xHis TEV DRP
ns with redox properties) 
moter/terminator, a 6HIS tag for nickel affinity purification, a Tobacco
(DRP). The 6HIS tag is N-terminal for the 6HIS plasmid (A) and for
sion partner and the TEV site for fusion with redox properties
fusions are represented in blue. The same representation of the redox
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Figure 2 Schematic representation of the high throughput expression screening procedure. For details, see Materials and methods.
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nickel affinity purification, systematic analysis of the
Labchip GXII electropherograms was performed to
determine the concentration of the purified proteins and
compare the apparent molecular weight of the purified
fusion proteins with their expected theoretical molecular
weight. After incubation with the protease TEV to
remove the fusion partner, the cleavage was confirmed
by analysis on the Labchip GXII and the accurate mass
and oxidation state of each peptide were determined by
mass spectrometry. Whenever possible, functional assays
were performed to demonstrate the accuracy of their
folding.
Influence of the fusion partner and strains on soluble
expression
An exhaustive analysis of the 1008 conditions tested (28
proteins x 12 fusion partners x 3 strains) was performed
in parallel (Figures 3, 4 and 5). The amounts of soluble
fusion proteins were estimated after the nickel purifica-
tion using the Caliper GX II semi quantitative method
(See Materials and Methods). The experiments on the1008 cultures were performed in duplicates. The soluble
level was in good agreement between the two experi-
ments and therefore the soluble yields were averaged be-
tween the two experiments and ranked according to
four categories of soluble level: not detected, soluble
from 0.1 to 10 mg/L, 10 to 20 mg/L and greater than 20
mg/L. The limit of 20 mg/L was dictated by the volume
of nickel beads used in the expression screening protocol
(50 μL); a volume suitable to detect low expressing pro-
teins (> 0.1 mg/L of culture with Caliper GX II detec-
tion) but saturated with soluble levels above 20 mg/L
[9,49]. While the expression screening protocol used in
this study gave a good indication of the soluble level and
while it allowed the ranking of the impact of the fusion
based on soluble yields, it was not designed to discrimin-
ate between several conditions that would all give
soluble levels above 20 mg/L. In this study, at prepara-
tive scale, the purified fusion proteins were sometimes
above 200 mg/L (see “Functional characterization”). This
prompted us to design a modified expression screening
protocol (based on 200 μL of beads [49]) that was vali-
dated on the high expressing fusions of this study and
28 DRPs Fold SSBonds
Amino 
acids 12 Fusion Partners
Conditions with 
soluble 
expression
6HIS Gb1 ZZ Trx-P Trx-C Trx Trx-A Trx-G MBP GST DsbA DsbC
Androctonin 2 25 + + + + + + ++ + ++ +++ 10
TNF receptor 2 26 + + + +++ 8
ω-MVIIC ICK 3 25 + + + + + + ++ ++ ++ ++ 10
ω-MVIIA ICK 3 25 + ++ ++ + +++ ++ +++ 7
mCD4M61 α/β 3 27 + +++ + ++ 4
D-Psp-COOH ICK 3 28 + + + + + + + ++ +++ 9
Trypsin Inhibitor II ICK 3 30 + + + + ++ + + +++ ++ +++ 10
Scyllatoxin α/β 3 31 + + + + + + +++ 7
EVIA-O6P ICK 3 32 + + + + + + + 7
ShK Toxin 310αα 3 35 + + + 3
Psalmotoxin-1 ICK, 310 3 40 + ++ ++ +++ ++ ++ +++ +++ +++ + 10
LDTI Kazal Type 3 40 + + + + ++ + + ++ ++ ++ 10
Thrombin Inhibitor infestin Kazal Type 3 46 + + + + + ++ + +++ +++ + 10
BPTI Kunitz 3 58 + + + + + + + + ++ 9
TDPI Kunitz 4 52 ++ + 2
C13S1C1 3FT 4 59 + + + + + + ++ 7
Fasciculin I 3FT 4 61 + ++ + + + 5
MT3 3FT 4 65 + + + + + + + + + ++ 10
MT7 3FT 4 65 + + + ++ + + ++ ++ +++ 9
MT1 3FT 4 65 + + + + + + + ++ 8
MTx2 3FT 4 65 + ++ + ++ ++ +++ +++ 7
AdTx1 3FT 4 65 + + + ++ 4
AdTx2 3FT 4 66 + + + + + 5
MTalpha 3FT 4 66 ++ + + 3
AcrI 4 69 + + ++ ++ ++ +++ +++ ++ 8
SLURP 3FT 4 72 + + ++ + +++ 5
DA1JDE 3FT 5 65 ++ + + 3
RBI 5 122 + + +++ + + ++ 6
6HIS Gb1 ZZ Trx-P Trx-C Trx Trx-A Trx-G MBP GST DsbA DsbC Total
0 0 12 12 16 18 18 19 24 25 25 27 196
Estimation of soluble concentration :
Not detectable
0.1 to 10 mg/L + Fusion partner without redox properties
10 to 20 mg/L ++
more than 20 mg/L +++ Fusion partner with redox properties
Figure 3 Impact of 12 different fusion partners on the solubility of DRP in the strain BL21 (DE3) pLysS. The DRPs are ordered by
increasing number of disulfide bonds and amino acids. The protein fold (where known) is indicated. The fusions are ranked according to the
number of soluble DRPs detected. When the number of soluble conditions is the same they are ranked according to the number of DRP fusions
produced above 10 mg/L. These rankings are kept throughout Figure 3 to 5.
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(data not shown).
Out of 336 constructs in BL21 (DE3) pLysS, soluble
expression of fusion proteins was observed in the milli-
gram range of protein per liter of culture in 196 cases
(58%), with correct apparent molecular weights (Figure 3).
Fusion with MBP, GST, DsbA and DsbC partners resulted
in soluble expression of most of the DRPs (more than 85%
for MBP, GST and DsbA and more than 95% for DsbC).
Fusion with the different thioredoxins or ZZ was success-
ful, but less effective, with soluble expression rates ranging
from 40% to 70%. Soluble expression was observed neither
with the sole 6HIS tag nor with the fusion Gb1, where
DRPs in fusion were often detected as inclusion bodies
(data not shown). As shown in Figures 3 and 6, the four
best solubilizing fusions (MBP, GST, DsbA and DsbC) not
only gave access to a wider variety of soluble DRPs butalso gave higher amounts of soluble protein for the 12
fusions tested. Many DRPs were expressed with significant
expression levels when fused with those four partners.
Specifically, 18 DRPs out of 28 were expressed with
expression levels greater than 10 mg/L of fusion protein
using DsbC as a fusion partner (Figure 6). This number is
significantly higher with DsbC than for any of the other
fusion partners tested (Figure 6).
In contrast, soluble expression was observed in only 44
conditions for the Origami B (DE3) pLysS strain (Figure 4)
and in only 50 conditions in the strain SHuffle® T7
Express lysY (Figure 5) as compared to 196 with BL21
(DE3) pLysS strain (Figure 3). The estimated amounts of
soluble fusion proteins obtained in both strains were
almost always lower or in the best cases only similar to
those produced in the same condition in BL21 (DE3)
pLysS. For the Origami B (DE3) pLysS, the fusion with
28 DRPs Fold SSBonds
Amino 
acids 12 Fusion Partners
Conditions with 
soluble 
expression
6HIS Gb1 ZZ Trx-P Trx-C Trx Trx-A Trx-G MBP GST DsbA DsbC
Androctonin 2 25 + + 2
TNF receptor 2 26 + + 2
ω-MVIIC ICK 3 25 + 1
ω-MVIIA ICK 3 25 + + 2
mCD4M61 α/β 3 27 + + 2
D-Psp-COOH ICK 3 28 + + 2
Trypsin Inhibitor II ICK 3 30 + ++ 2
Scyllatoxin α/β 3 31 + + + 3
EVIA-O6P ICK 3 32 0
ShK Toxin 310αα 3 35 0
Psalmotoxin-1 ICK, 310 3 40 ++ 1
LDTI Kazal Type 3 40 ++ 1
Thrombin Inhibitor infestin Kazal Type 3 46 + ++ 2
BPTI Kunitz 3 58 + + + 3
TDPI Kunitz 4 52 + + 2
C13S1C1 3FT 4 59 0
Fasciculin I 3FT 4 61 0
MT3 3FT 4 65 + + + + 4
MT7 3FT 4 65 + + 2
MT1 3FT 4 65 + 1
MTx2 3FT 4 65 + + + 3
AdTx1 3FT 4 65 + + 2
AdTx2 3FT 4 66 + + 2
MTalpha 3FT 4 66 + 1
AcrI 4 69 + 1
SLURP 3FT 4 72 + 1
DA1JDE 3FT 5 65 0
RBI 5 122 + + 3
6HIS Gb1 ZZ Trx-P Trx-C Trx Trx-A Trx-G MBP GST DsbA DsbC Total
0 0 0 0 1 0 0 0 16 21 2 4 44
Estimation of soluble concentration :
Not detectable
0.1 to 10 mg/L + Fusion partner without redox properties
10 to 20 mg/L ++
more than 20 mg/L +++ Fusion partner with redox properties
Figure 4 Impact of 12 different fusion partners on the solubility of DRP in the strain Origami B (DE3) pLysS.
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ity of DRPs (57% and 75% respectively) while soluble
expression with thioredoxins, DsbA and DsbC were only
observed in rare cases (< 1%, <10% and <15% respect-
ively). Out of the 44 soluble conditions, the soluble level
was mainly achieved at very low concentrations (90% of
the cases are below 10 mg/L) except in the cases of four
GST fusions.
For the SHuffle® T7 Express lysY, the fusion with MBP
was the only one allowing the soluble expression for a ma-
jority of DRPs (71%). The successful soluble expression
with ZZ and thioredoxins (below or around 5%) was very
rare while the fusion with DsbA and DsbC (40%) was far
from the same as cultures in BL21 (DE3) pLysS, but sig-
nificantly better than in Origami B (DE3) pLysS. Out of
the 50 soluble conditions, the soluble level was mainly
achieved at very low concentrations (78% of the cases are
below 10 mg/L). Most of the 22% that were expressed be-
tween 10 to 20 mg/L were expressed as MBP fusions.In our set-up, the differences observed between BL21
(DE3) pLysS versus Origami B (DE3) pLysS and SHuffle®
T7 Express lysY were important, both in terms of num-
ber of soluble constructs and yields. In particular, of the
28 DRPs the soluble yield obtained with the Origami B
(DE3) pLysS or the SHuffle® T7 Express lysY was never
better than the yield of the equivalent condition in BL21
(DE3) pLysS. For these reasons, we have chosen to focus
on the production of DRPs using only the strain BL21
(DE3) pLysS in the rest of the study.
Influence of the fusion partner on oxidation
Next, an extensive analysis of the oxidation state of the
DRPs was performed by MALDI-TOF. As MALDI-TOF
analyses with isotopic resolution are limited to very
small proteins, only the 12 DRPs with a molecular mass
lower than 6500 Da could be analyzed (Figure 7). All the
constructs yielding soluble fusion proteins for those 12
DRPs in the strain BL21 (DE3) pLysS (96 out of 120)
28 DRPs Fold SSBonds
Amino 
acids 12 Fusion Partners
Conditions with 
soluble 
expression
6HIS Gb1 ZZ Trx-P Trx-C Trx Trx-A Trx-G MBP GST DsbA DsbC
Androctonin 2 25 ++ + 2
TNF receptor 2 26 ++ ++ 2
ω-MVIIC ICK 3 25 + + + 3
ω-MVIIA ICK 3 25 ++ ++ + + 4
mCD4M61 α/β 3 27 + 1
D-Psp-COOH ICK 3 28 ++ 1
Trypsin Inhibitor II ICK 3 30 + + + + + + + + 8
Scyllatoxin α/β 3 31 + + + 3
EVIA-O6P ICK 3 32 0
ShK Toxin 310αα 3 35 + 1
Psalmotoxin-1 ICK, 310 3 40 + + 2
LDTI Kazal Type 3 40 ++ + + 3
Thrombin Inhibitor infestin Kazal Type 3 46 ++ + 2
BPTI Kunitz 3 58 + + 2
TDPI Kunitz 4 52 0
C13S1C1 3FT 4 59 + 1
Fasciculin I 3FT 4 61 + 1
MT3 3FT 4 65 + 1
MT7 3FT 4 65 + 1
MT1 3FT 4 65 + 1
MTx2 3FT 4 65 ++ ++ + + 4
AdTx1 3FT 4 65 + + + 3
AdTx2 3FT 4 66 0
MTalpha 3FT 4 66 0
AcrI 4 69 + + + 3
SLURP 3FT 4 72 0
DA1JDE 3FT 5 65 0
RBI 5 122 ++ 1
6HIS Gb1 ZZ Trx-P Trx-C Trx Trx-A Trx-G MBP GST DsbA DsbC Total
0 0 1 2 2 1 1 1 20 0 11 11 50
Estimation of soluble concentration:
Not detectable
0.1 to 10 mg/L + Fusion partner without redox properties
10 to 20 mg/L ++
more than 20 mg/L +++ Fusion partner with redox properties
Figure 5 Impact of 12 different fusion partners on the solubility of DRP in the strain SHuffle® T7 Express lysY.
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TOF analysis. Amongst these 96 constructs, the mono-
isotopic masses corresponding to the correctly oxidized
species were detected in 81 cases (See Figure 7: condi-
tions in green). In all analyses performed, the MALDI-TOF
spectra matched the theoretical isotopic distribution for
the DRP with fully oxidized cystines (see Figure 8A: experi-
mental MALDI-TOF spectrum obtained for mCD4M61).
The reduced forms of the proteins could not be detected
(data not shown), probably due to aggregation or precipita-
tion. Oxidized proteins were detected in a large majority of
cases when fused to partners with redox activity (between
70 to 100% for thioredoxin and its mutants, 92% for DsbA
and 100% for DsbC, see Figure 7). This percentage is lower
when fusions have only a solubilizing role (60% for ZZ,
70% for MBP, 58% for GST). To access the oxidation state
of DRPs larger than 6500 Da, we also analyzed selected
DRPs in fusion with their solubilizing partner with anLTQ-Orbitrap mass spectrometer. As DsbC was by far the
best fusion partner among those investigated, the exact
masses of 25 DsbC-DRP fusions were determined. These
analyses demonstrated that out of these 25 samples, 17
fusion proteins had molecular masses in agreement with
the expected masses considering fully oxidized cystine resi-
dues, with a mass difference between the observed and
expected masses of less than 0.7 Da on average (Additional
file 3: Table S3).
As mass spectrometry analyses revealed that oxidized
DRPs were detected in many cases, we tried to determine
if the formation of disulfide bonds occurred in the cyto-
plasm of BL21 (DE3) pLysS or during the subsequent
extraction and purification steps. To elucidate this ques-
tion, we investigated the particular case of mCD4M61 pro-
duced in fusion with DsbC. A thiol-blocking agent, N-ethyl
maleimide (NEM) was introduced in the lysis buffer to
prevent ex vivo oxidation. NEM readily reacts with free
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Figure 6 Impact of the fusion partner on the number of soluble proteins. White: Non-redox fusions. Blue: redox fusions. Bars represent the
number of soluble DRPs produced above 10 mg/L of culture in fusion with the specified partner. The strain used is BL21 (DE3) pLysS.
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ment per alkylated cysteine. However, as NEM does not
react with cystines involved in disulfide bridges, NEM
treatment would leave in vivo oxidized mCD4M61 un-
modified. After lysis and incubation in the presence of 100
mM NEM, purification and TEV cleavage were performed
as in the previous experiments. MALDI-TOF analysis re-
vealed the presence of a major peak at m/z 3728.14 inFusio
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Figure 8 MALDI-TOF analysis of mCD4M61. Panel A: Comparison of the experimental MALDI-TOF spectrum obtained for the mCD4M61 with
the theoretical isotopic distributions of fully reduced and fully oxidized mCD4M61. The mCD4M61 DRP was produced using DsbC as fusion
partner. Panel B: Experimental MALDI-TOF spectrum obtained for the mCD4M61 using N-Ethylmaleimide as an alkylating agent during cell lysis.
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mCD4M61 mostly occurred ex vivo (Figure 8B).
Functional characterization
Functional characterization through an activity test is
one of the best methods to discriminate DRPs with their
native fold and correct disulfide patterns from misfolded
isoforms. Purifications from larger scale cultures using
BL21 (DE3) pLysS were performed on six selected DRPs
(mCD4M61, Trypsin Inhibitor II, LDTI, Thrombin In-
hibitor Infestin, BPTI and MT7) for which functional
tests are available. DsbC was chosen as a fusion partner
because it gave the highest yields of soluble and oxidized
protein in the analytical screen. Very large amounts of
DsbC-DRP fusion proteins were obtained after nickel
affinity purification, ranging from 90 mg for the
mCD4M61 fusion to 291 mg for the Trypsin Inhibitor II
fusion. Fusion proteins were digested with TEV protease
to release the DRPs. After purification to homogeneity
using reverse phase HPLC (i.e. >95%), all DRPs were
produced in quantities varying between 0.8 and 12 mg/L
(Table 1), except for the muscarinic toxin MT7 for
which only a few micrograms were obtained. The func-
tional tests of these 6 proteins revealed that they were
fully active (Table 1) with inhibition constants similar to
the values reported in the literature [51-55], leading usto conclude that these DRPs were produced with their
natively folded structures.Discussion
We have developed a high throughput expression screen
that enabled us to assess the solubility of DRPs fused to
a large number of partners. We used it to study the im-
pact of twelve fusion tags and three expression strains
on the soluble level of 28 DRPs. Here, we show that a
general scheme for bacterial expression in the cytoplasm
of E. coli of genes coding for DRPs could be successfully
implemented. Our approach consists of (i) cloning by
recombination of genes in our set of vectors, (ii) cultur-
ing of E. coli in auto-induction media for the expression
of fusion proteins in the cytoplasm (iii) lysis of bacteria,
nickel affinity purification and analysis of fusion pro-
teins, (iv) digesting with TEV and MALDI-TOF detec-
tion of oxidized DRPs. In the present study, we
identified the conditions leading to soluble expression of
the 28 selected DRPs in E. coli. Amongst the 1008 con-
ditions tested in duplicates (28 proteins x 12 fusions x 3
strains), 196 conditions allowed soluble expression in
the strain BL21 (DE3) pLysS, whereas only 44 and 50 con-
ditions gave soluble expression for the strain Origami B
(DE3) pLysS and SHuffle® T7 Express lysY, respectively.
Table 1 Functional validation of purified DRPs
Functional test
Disulfide Rich
Peptide
Fold SS DsbC fusion
produced (mg/L)
Theoretical
DRP (mg/L)
Purified DRP
(mg/L)
DRP
yield
Detected
mass
Test Observed vs
Expected
mCD4M61 α/β 3 90 8.9 3.5 39% 2972.0 ± 0.5 ELISA 69 nM (32 nM)
Trypsin Inhibitor II ICK 3 291 30.1 0.9 3% 3124.4 ± 0.3 Trypsin
Inhibition
1.0 nM (0.3 nM)
LDTI Kazal Type 3 240 35.0 12.0 34% 4572.1 ± 0.1 Trypsin
Inhibition
1.8 nM (1.8 nM)
Thrombin
Inhibitor Infestin
Kazal Type 3 120 20.2 0.8 4% 5507.7 ± 0.2 Trypsin
Inhibition
1.8 nM (2 nM)
BPTI Kunitz 3 180 35.1 3.0 9% 6567.6 ± 0.1 Plasmin
inhibition
0.4 nM (0.14 nM)
MT7 3FT 4 160 34.7 0.007 < 0.03% 7529.9 ± 0.6 binding
mAChR
5 pM (29 pM)
Purification from 1 liter culture of DsbC-DRP fusion in BL21 (DE3) pLysS strain.
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pLysS or SHuffle® T7 Express lysY and the BL21 (DE3)
pLysS strain cannot be explained by medium compos-
ition, expression plasmids or cultivation differences, as
all tests were run in the same conditions. Furthermore,
thanks to the removal of the antibiotics used to maintain
the trxB-/gor- genomic mutations in Origami (DE3)
pLysS and SHuffle® T7 Express lysY, the growth rate of
the three strains were very similar. An increased lag
phase was observed with the Origami B (DE3) pLysS
and SHuffle® T7 Express lysY but at harvesting time, in
stationary phase, the optical density of the 672 cultures
was in all cases around 12 (with less than 10% differ-
ence) and therefore the yield of soluble expression was
considered as normalized by bacterial biomass. The low
number of soluble constructs in Origami B (DE3) pLysS
and SHuffle® T7 Express lysY is directly associated with
low production levels. In practically all cases these two
strains produced lower amounts of soluble fusion pro-
tein than BL21 (DE3) pLysS and out of the 28 DRPs,
none would be favorably produced in Origami B (DE3)
pLysS or SHuffle® T7 Express lysY as opposed to BL21
(DE3) pLysS. The low production level of DRPs in in
Origami B (DE3) pLysS or SHuffle® T7 Express lysY was
confirmed with scale-up tests (unpublished observations).
Strikingly, soluble expression of DRP fusions in
Origami B (DE3) pLysS or SHuffle® T7 Express lysY are
mostly observed with fusion partners lacking redox
activity like GST or MBP for Origami B (DE3) pLysS
and MBP for the SHuffle® T7 Express lysY. Only a few
constructs were soluble using redox-active fusion part-
ners (Trx, Trx mutants, DsbA and DsbC) and at levels
below the equivalent BL21 (DE3) pLysS cultures. In spite
of this, SHuffle® T7 Express lysY performed better with
DsbA and DsbC than Origami B (DE3) pLysS. These
results contrast with the good results of redox-active
fusion partners in the strain BL21 (DE3) pLysS. This israther unexpected since redox-active proteins such as
thioredoxin or DsbC are often described as enhancing
disulfide bond formation in the cytoplasm of Origami B
(DE3) pLysS or equivalent strains either when co-
expressed [36,56] or used as a fusion partner [57]. The
low production levels in Origami B (DE3) pLysS and
SHuffle® T7 Express lysY strains might be linked to the
fact that these strains are not as robust as other strains
like BL21 (DE3) pLysS, often having altered growth
parameters compared to other E. coli strains [9,58]. It is
important to note that the trxB-/gor- strains only have
the reducing pathways of the cytoplasm disrupted. This
means that once a disulfide bond is formed, it is more
likely to be retained than in a reducing cytoplasm, how-
ever, it does not necessarily make disulfide bond forma-
tion more efficient. Firstly, there are no added catalysts
for de novo disulfide bond formation present to promote
disulfide bond formation in the first place. In addition,
while oxidation in the non-reducing cytoplasm can
occur by the transfer of disulfide bonds to folding pro-
teins from oxidized thioredoxin (which can no longer be
reduced by the canonical pathway due to the trxB-/gor-
mutation), this is relatively inefficient and slow [59]. It
has been suggested that correct folding in a trxB-/gor-
background is to the detriment of yield [60] and accord-
ingly, these strains have been reported to often produce
very low yields [61,62]. In fact, even with the co-
expression of DsbC to catalyze disulfide isomerization,
yields of oxidized correctly folded protein can only be
improved if (i) the expressed protein is soluble (perhaps
necessitating the use of additional solubilizing fusion
tags), and (ii) if the disulfide bonds are already formed
(either spontaneously or by interaction with other disul-
fide bond donor proteins, including DsbC itself ). These
reasons may explain why soluble yields from SHuffle
strains have not been improved beyond those found in
Origami strains for the expression of certain proteins
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(DE3) pLysS or SHuffle® T7 Express lysY might necessi-
tate screening of additional parameters such as medium,
induction conditions, temperatures [36] or protein co-
expression that were not investigated in our study. How-
ever, in our set-up, the difference observed between BL21
(DE3) pLysS and Origami B (DE3) pLysS or SHuffle® T7
Express lysY was significant and we have chosen to focus
only on the strain BL21 (DE3) pLysS.
In contrast to Origami B (DE3) pLysS or SHuffle® T7
Express lysY, the success rates of DRPs expressed as
fusions in the cytoplasm of BL21 (DE3) pLysS was high
(196/336). For every DRP of interest, multiple soluble
expression conditions were observed. Our procedure
yields relatively high quantities of fusion proteins after
nickel affinity purification: approximately 20% of the
conditions tested led to estimated quantities greater than
10 milligrams per liter of culture (65/336). Quantities of
fusion proteins are higher with MBP, GST, DsbA and
DsbC than for the other fusion partners. Use of
thioredoxin and thioredoxin mutants could be an inter-
esting option, because of their lower molecular weight
compared to the other fusion partners (15 kDa vs 25–40
kDa), thereby providing a greater proportional yield of
DRPs to fusion tag [13]. Even so, from the data collected
here, the impact of the thioredoxin mutations is difficult
to appreciate, both in terms of solubilization and quan-
tities of fusion.
To investigate the redox states of the DRPs when pro-
duced in fusion, we have coupled the solubility screen
with MS detection of the proteins whenever possible.
MALDI-TOF analyses revealed that detectable amounts
of oxidized proteins can be cleaved off from the fusion
partners in a very high number of cases using BL21
(DE3) pLysS as a production strain. These observations
raised the question of whether the disulfide bond forma-
tion occurred in vivo or ex vivo. The ex vivo formation
of disulfide bonds is a hypothesis also suggested previ-
ously by Tedford et al. [63] based on the equivalent
oxidized production of a single spider toxin in BL21
versus a trx- strain. Thus, to test this hypothesis, the
disulfide bond status of mCD4M61 fused with DsbC was
examined by subjecting the lysate to addition of N-
ethylmaleimide at the moment of cell lysis. In contrast
with the untreated samples, oxidized mCD4M61 could
not be detected after purification and TEV cleavage,
indicating that the disulfide bond formation probably oc-
curred ex vivo. The strain BL21 (DE3) pLysS allows the
production of high amounts of DRPs fused with differ-
ent partners but its cytoplasm probably remains an un-
favorable environment for the formation of disulfide
bonds. In contrast, the purification steps after cell lysis
probably provide a more favorable environment for the
DRP to reach an oxidized state. Purification steps notonly remove the reducing pathway components that
could hamper the disulfide bond formation but are also
performed at pH 8, rendering protein thiols (typically
pKa ∼ 8–9) very reactive. The buffer also has higher con-
centrations of molecular oxygen that can act as final
electron acceptors and thus be the driving force leading
to the oxidation of the peptide.
The data collected suggest that the redox properties of
the fusion partner might have an effect on the folding of
the DRPs. First, we have shown that either redox-
inactive (MBP, GST) or redox-active (DsbC, DsbA)
fusion partners are able to produce significant quantities
of fusion proteins for many DRPs. However, MALDI-
TOF experiments revealed that constructs for which
oxidized peptide could not be detected are, in most
cases, fusions without redox properties (e.g. MBP, GST).
In contrast, most oxidized DRPs are detected when
thioredoxins, DsbA or DsbC were used as fusion part-
ners. These observations support the hypothesis that
redox activity of the carrier has an influence on the fold-
ing of the DRP, even if oxidation occurs ex vivo. When
using fusion partners with redox activity, the partner
could not only improve the solubility of the folding
intermediates but could also assist the DRPs to reach
their native oxidized form. To further confirm this hy-
pothesis, it could be interesting to investigate the effect
of inactive redox variants of those partners on the yield
of active DRP.
Under our criterions, use of DsbC as a fusion partner
in the strain BL21 (DE3) pLysS was the most potent
combination tested. Indeed, use of DsbC yielded soluble
fusions for almost all the DRPs (27/28) but also has the
strongest effect on the quantity of fusions produced.
When DsbC is used as a fusion partner, more than 67%
of the constructs (18/28) are produced with yields
exceeding 10 mg/L at the screening scale. The true mag-
nitude of those yields becomes even more apparent
when proteins are expressed at larger scale (1 liter) with
up to 290 mg/L for the DsbC fusions. Foremost, mass
spectrometry experiments also revealed that DsbC
generates oxidized folded DRPs in a significant number
of cases. The favorable results obtained with DsbC can
be explained by its excellent solubilization potential but
most importantly by its isomerase and chaperonin activ-
ities [17], which are a considerable advantage to assist
DRPs to reach their native active state. Most import-
antly, depending on the DRP properties, the proportion
of folded DRP can be very significant as attested by the
good yields obtained for scale-up production and purifi-
cation using DsbC as fusion partner (e.g. LDTI, BPTI,
mCD4M61, Table 1).
Only a few articles available in the literature report the
successful production of oxidized DRPs in the E. coli
cytoplasm without the use of trxB-/gor- strains or
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production of active viscotoxin A3 containing three di-
sulfide bonds using thioredoxin as a fusion partner [13].
Similarly, Mac et al. reported production of Endothelin-
1 containing two disulfides using thioredoxin [64], while
Tedford et al. used a GST-fusion for the production of
an insecticidal spider toxin containing three disulfide
bonds [63]. Our present work shows that many other
DRPs can be produced and purified to homogeneity at
the milligram scale using our protocols, spanning a
diversity of folds (α/β, ICK, Kazal type, Kunitz). We
observed that some proteins tested were more prone to
adopt their oxidized native conformation than others. As
an illustration, we can see that mCD4M61, Psalmotoxin-
1 and LDTI were detected in MALDI-TOF analyses in
virtually all cases, independently of the fusion partner
used. On the contrary, EVIA and ShK toxins were only
detected in a few conditions tested. In addition, yields
from large-scale expression of DRPs were quite case-
dependent, ranging from a few micrograms for the hard-
to-express muscarinic toxin MT7 containing four disulfide
bonds to more than 12 mg for LDTI. In some cases, the
amounts of DRPs obtained after all production and purifi-
cation steps are lower than what could be expected from
the amounts of fusion protein produced. It has to be
noted that no individual optimization was performed to
increase yield for individual DRPs. Thus, one could rea-
sonably expect to increase yields by improving the process
for a specific protein (buffers, purification, choice of the
protease) or by performing further in vitro refolding steps.
While this optimization would be an interesting option
to increase yields, one should also consider other tools
to encourage increased efficiency of correct peptide fold-
ing. Indeed, the ratios between purified DRPs versus
purified fusion proteins suggest that the folding of some
proteins is particularly incomplete (e.g. MT7, Thrombin
Inhibitor Infestin or Trypsin Inhibitor II). Among the
further improvements envisioned, it may be of interest
to express concomitantly and in stoichiometric excess a
second redox-active protein (oxidase or isomerase) to
boost the positive effect of DsbC. Besides that, the lysis
buffer components could possibly have an influence on
the DRP folding. Given the hypothesis of an ex vivo
oxidation it would be of interest to investigate the effect
of introducing oxidized/reduced glutathione which are
classically used for in vitro DRP refolding strategies.
Additionally, use of tools promoting the in vivo folding
and oxidation of the DRP would be an interesting option
to achieve higher productivity. Co-expression of sulfhy-
dryl oxidases [61,62,65] or addition of redox molecules
in the medium [66] could be promising options to pro-
mote the formation of disulfides bonds in vivo. These
tools could be additionally introduced in our screen
without significant modification of the process.Conclusion
Our high throughput screening approach allows the sys-
tematic investigation of the solubilizing and folding
influence of various partners in the strains BL21 (DE3)
pLysS, Origami B (DE3) pLysS and SHuffle® T7 Express
lysY for the production of soluble DRPs. In spite of its
reducing cytoplasm, BL21 (DE3) pLysS is a very efficient
strain for the production of DRPs in fusion with solubil-
izing partners. In our set-up, trxB-/gor- strains Origami
B (DE3) pLysS and SHuffle® T7 Express lysY yielded only
very low amounts of fusion proteins. Many DRPs are
found oxidized after production in BL21 (DE3) pLysS,
most probably because of post-lytic oxidation reactions.
In many ways, use of DsbC as a fusion partner in the
strain BL21 (DE3) pLysS was the most potent combin-
ation tested. Our protocols allow the production of a
large diversity of DRPs using DsbC as a fusion partner,
leading to pure active DRPs at milligram scale in many
cases. Thus, this work should facilitate the study of
DRPs with therapeutic or biotechnological interest
whose production was previously a limiting step.
Materials and methods
Design and construction of the expression plasmid library
Synthetic genes optimized for recombinant expression of
miniproteins in E. coli were ordered from Geneart AG.
These genes contain the sequence coding for a TEV pro-
tease cleavage site (ENLYFQ/G) followed by the se-
quence corresponding to the DRP (see Additional file 1:
Table S1), with Gateway recombination sites on each ex-
tremity of the gene. These synthetic constructs were
cloned by Gateway™ BP cloning technology using
pDONR221 as a donor vector. Twelve Gateway destin-
ation vectors were used in this study. Each contains one
of the eleven fusion partners and a 6HIS tag for protein
purification located either on the N- or C-terminal side
of the fusion partner and the twelfth vector containing
6HIS alone (see Additional file 2: Table S2). The 28 entry
clones were in turn recombined using the Gateway™ LR
cloning technology using one of the 12 Gateway destin-
ation vectors. Thus, a total of 336 different expression
plasmids were created. All cloning steps (Gateway LR
cloning of the 28 pENTR clones in 12 destination vec-
tors, DNA purifications, bacterial transformations and
cultures) were accomplished within a week using high
throughput compliant protocols detailed elsewhere [9].
High throughput protein expression screening
In this study, all cultures were grown in auto-induction
medium ZYP-5052 supplemented with antibiotics both
for small-scale expression screens (in BL21 (DE3) pLysS,
Origami (DE3) pLysS and SHuffle® T7 Express lysY) or
scale-up expression (in BL21 (DE3) pLysS). ZYP-5052
medium is a buffered complex medium containing
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tein expression after glucose depletion [50]. Expressions
were performed using a standardized two-step process.
In the first part of fermentation, cells were grown at 37°
C to quickly reach the glucose depletion phase just be-
fore the induction. After that step (4 hours) the
temperature was lowered to 17°C for 18h to favor pro-
tein folding and soluble protein expression.
All steps were carried out in 24 or 96 deep-well plates
(DW24 and DW96, respectively). Expression strains
were obtained after a heat-shock transformation of com-
petent cells with the expression plasmids. Transformed
cells were used to inoculate pre-cultures in DW96 plates
containing 1 mL of LB media in each well. The following
morning, 100 μL of the pre-culture broth was used to
inoculate 4 mL of ZYP-5052 medium. Cultivation was
carried out using DW24 plates to increase the biomass
compared to DW96 cultures. After an overnight incuba-
tion at 17°C, cells were pelleted by centrifugation,
resuspended in lysis buffer and transferred into DW96
and frozen at −80°C. After thawing the cells the lysate
was purified using an automated nickel affinity proced-
ure as described in Figure 2. The whole procedure for
the BL21 (DE3) pLysS and Origami B (DE3) pLysS (672
cultures followed by purification and analysis), was
performed within a week and reproduced a second time
to confirm the results (these protocols have been de-
tailed elsewhere [9,49]) while the SHuffle® T7 Express
lysY experiment was done on a separate week.
Identification of soluble expression conditions
In this study, the analysis of the purified protein yields
(as well as the efficiency of TEV cleavage) was performed
on a Labchip GXII (Caliper, USA) microfluidic high
throughput system, which was more adapted to the
throughput of this work than traditional SDS-PAGE
analysis. This analysis (done following the manufac-
turer’s instructions) provides an estimation of the mo-
lecular weight, concentration and purity of the proteins
with a detection limit of approximately 0.1 mg/L of cul-
ture. Proteins below 5 kDa could not be assessed by
this method due to system limits. For the DRPs below
this molecular weight, the cleavage efficiency was ini-
tially assessed by the disappearance of the fusion-DRP
species. The molecular weight of the free DRP was only
confirmed by mass spectrometry at scale up.
Large-scale cultures, purification and cleavage of
DsbC-DRPs
For larger scale production of recombinant proteins, a
Fernbach flask containing 1 L of ZYP-5052 auto-induction
medium and the appropriate antibiotics was inoculated
with an overnight culture of BL21 (DE3) pLysS to reach
0.05 O.D. at 600 nm. Cultures were performed using thetwo-step protocol (4h at 37°C then 18h at 17°C). At the
end of culture, cells were then harvested by centrifugation
(4500 × g, 30 min, 4°C) and the pellet was resuspended in
50 mL of lysis buffer (100 mM Tris–HCl, pH 8, 150 mM
NaCl, 5% glycerol). Lysis of cells was performed using
a cell disrupter (Constant System Ltd). The lysate was
cleared by centrifugation (18 000 rpm, 30 min, 4°C)
and the supernatant loaded onto a 5 mL HisTrap FF
column (GE-Healthcare Bio-Sciences). The 6HIS-
tagged fusion proteins were then eluted with a linear
gradient (0 to 100% B in 30 min at a flow rate of 2 mL/
min) of buffer B (100 mM Tris–HCl, pH 8, 150 mM
NaCl, 5% glycerol, 500 mM imidazole) in buffer A (100
mM Tris–HCl, pH 8, 150 mM NaCl, 5% glycerol, 40
mM imidazole). The fractions containing the 6HIS-
tagged fusion protein were pooled and dialyzed for 3h
against lysis buffer using a Spectra/Por® Dialysis Mem-
brane (MWCO: 3500). The protein of interest was then
cleaved with 10% (w/w) TEV protease overnight at 4°C
and purified by RP-HPLC. RP-HPLC purification was
performed using a semi-preparative C4 column (Vydac
214TP1010, 10 μm, 300 Å, 10 × 250 mm) using a linear
gradient 0-60% in 30 min of solvent B (100% acetonitrile,
0.09% TFA) in solvent A (100% H2O, 0.1% TFA) with a
flow rate of 4 mL/min. After HPLC purification, DRPs
were lyophilized and solubilized in the appropriate buffer
for further studies.Characterization by mass spectrometry
Detection of oxidized DRPs used MALDI-TOF and LTQ-
Orbitrap. The purified fusion protein samples were
digested by TEV protease at 4°C. Samples were loaded
onto C18 reverse phase ZipTips, desalted and eluted by
70% acetonitrile/ H2O /0.1% TFA before spotting on a
MALDI plate with 4-CHCA matrix at 10 mg/mL. MALDI-
TOF analyses were performed on a MALDI-TOF/TOF™
4800 Analyzer from AB-SCIEX (Foster City, CA). The iso-
topic pattern measured was compared with the theoretical
one determined from the amino acid sequences using
DataExplorer software (Version 4.9, Applied Biosystems).
High resolution/high mass accuracy measurements
were performed on an LTQ-Orbitrap instrument
(Thermo, San Jose, CA) by UHPLC-MS essentially as
described previously [67]. Briefly, DRP samples were
loaded and separated on a C18 Hypersil GOLD column
(2.1 mm x 150 mm, 175 Å, 1.9 μm, ThermoScientific) at
a flow rate of 300 μL/min with a linear gradient of 0 to
80% B in 10 min (with solvent A: H2O containing 0.1%
formic acid and solvent B: acetonitrile containing 0.1%
formic acid). MS acquisition was performed in the positive
ion mode from m/z 500 to 2000 using a resolution set at
30000 (at m/z 400). The resulting mass spectra were
deconvoluted using ProMass software (ThermoScientific).
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Enzyme inhibition by the inhibitors was tested in com-
petition experiments. For plasmin tests, we used 6 μM
fluorogenic substrate N-succinimyl-Ala-Phe-Lys-AMC
(Sigma Aldrich) and plasmin (Sigma Aldrich) at 0.1 nM
concentration in 100 μL of PBS buffer. For Trypsin tests,
we used 1.8 μM fluorogenic substrate Mca-R-P-K-P-V-
E-NVal-W-R-P-K(Dnp)-NH2 (R&D Systems) and Trypsin
(Sigma Aldrich) at 0.4 nM concentration in 200 μL of 50
mM Tris–HCl buffer pH 6.8, 100 mM NaCl, 10 mM
CaCl2.
The substrate and enzyme concentrations for the
experiments were chosen so as to remain well below
10% of substrate utilization and to observe the initial
rates. For each inhibitor, the percentage of inhibition
was determined in duplicate experiments at four inhibi-
tor concentrations, chosen to observe a 20–80% range of
inhibition. After 1h incubation with shaking at 25°C,
inhibition assays were performed by recording the fluor-
escence increase induced by the cleavage of fluorogenic
substrate, using 96-well nonbinding surface plates (3650
Corning-Costar plates). Fluorescence signals were monitored
using a Fluoroscan Ascent photon counter spectrophotom-
eter (ThermolabSystems) equipped with a temperature con-
trol device and a plate shaker. Ki values were determined
using the method proposed by Horovitz and Levitski [68].
The property of miniCD4 (mCD4M61) to inhibit the
binding of HIV-envelope was evaluated by in vitro competi-
tive ELISA as previously described [3]. The effect of MT7
on the equilibrium bonding of [3H]NMS on M1 muscarinic
receptor was determined in inhibition experiments as pre-
viously described [51].
Additional files
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Additional file 3: Table S3. Molecular masses of the 25 DsbC-DRP
fusions as determined by LTQ-Orbitrap mass spectrometer.
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